Navigation Links
In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
Date:6/23/2008

SCOTTSDALE, Ariz., June 23 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies hoping to identify the next blockbuster drug for pain management. The report, entitled "Thought Leader Insight & Analysis: Pain/Analgesics," is based on in-depth interviews conducted with a panel of specialists in anesthesiology, psychiatry, rheumatology, gastroenterology and primary care.

The diagnosis and treatment of nociceptive, neuropathic and somatic pain varies considerably depending on the physician specialty. MedPredict's panelists in each specialty outline their therapeutic goals and unmet needs in treating pain associated with cancer, fibromyalgia, trauma, rheumatoid and osteoarthritis, back injury, neuropathy, depression, migraine and Crohn's disease.

"Pain is subjective," said Dr. Jeffrey Berk, MedPredict's president. "If you think that you hurt, you hurt. This subjectivity makes the diagnosis and treatment of pain exceedingly difficult, and it presents enormous challenges for researchers trying to demonstrate analgesic efficacy versus placebo." One path to success will be to narrowly define the population being studied, as Lilly has done with duloxatine in diabetic neuropathy, according to Dr. Berk.

MedPredict's panelists predict successes and failures in a number of therapeutic targets, including mu receptor agonists/opioids, serotonergic/noradrenergics, sodium and calcium channel blockers, NMDA/glutamate, Alpha-2 agonist, (mGlu2/3), acetylcholine, AMPA, cannabinoid, NF Kappa b, TRPV1/vanilloids, stimulants, NSAIDs, hyaluronic acid, anti-IL-10 and anti-IL-1. They evaluate the development pipeline based on the medical potential, mechanism of action, reimbursement and regulatory environment and relevance of Schedule II status.

Companies/Partnerships discussed in this report include Allergan, Allergan/Acadia, Alpharma, Alpharma/Institut Biochimique, Amgen, Amgen/Takeda, Anesiva, AstraZeneca, Avigen, BioDelivery Services, Cephalon, Endo, Forest, Forest/Cypress/Pierre Fabre, Forest/Lundbeck, GlaxoSmithKline, Grunenthal/Ortho-McNeil, Japan Tobacco, Johnson & Johnson, King/Acura, Lilly, Merck, NeurogesX, Novartis, Pfizer, Regeneron, UCB, Wyeth.

The full report can be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Having Penetrated Israels Domestic Telephony Market, 012 Smile.Communications Prepares for Its Next Goal: Entering Israels Cellular Market
2. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
5. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
6. pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues
7. Biotech Drops Amid Tough Markets in February
8. ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve
9. Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLCs Regulatory Announcement
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):